Oncolytic viruses have made headlines owing to increasing numbers of reports of clinical success. Compelling data now indicate that small anticancer molecules can serve as potent sensitizers of tumour cells in hepatocellular carcinoma to enhance the oncolytic potential of systemically applied viruses.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
NCI-Staff. FDA approves talimogene laherparepvec to treat metastatic melanoma. National Cancer Institutehttps://www.cancer.gov/news-events/cancer-currents-blog/2015/t-vec-melanoma (2015).
Zhang, H. et al. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci. Transl Med. 9, eaam7996 (2017).
Lin, Y. et al. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proc. Natl Acad. Sci. USA 111, E4504–E4512 (2014).
Li, K. et al. Activation of cyclic adenosine monophosphate pathway increases the sensitivity of cancer cells to the oncolytic virus M1. Mol. Ther. 24, 156–165 (2016).
Mahoney, D. J. et al. Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell 20, 443–456 (2011).
Tardif, K. D. et al. Hepatitis C virus suppresses the IRE1–XBP1 pathway of the unfolded protein response. J. Biol. Chem. 279, 17158–17164 (2004).
Zhou, H. J. et al. Discovery of a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase (CB-5083). J. Med. Chem. 58, 9480–9497 (2015).
Russell, S. J., Peng, K. W. & Bell, J. C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658–670 (2012).
Miest, T. S. & Cattaneo, R. New viruses for cancer therapy: meeting clinical needs. Nat. Rev. Microbiol. 12, 23–34 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Altomonte, J. Sensitizing hepatocellular carcinoma to oncolytic virus therapy. Nat Rev Gastroenterol Hepatol 15, 8–10 (2018). https://doi.org/10.1038/nrgastro.2017.153
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2017.153